Category: 3. Business

  • United Group B.V. successfully completes €400 million bond refinancing

    United Group B.V. successfully completes €400 million bond refinancing

    United Group B.V., a leading telecommunications and media company in Southeastern Europe, today announces that it has successfully completed an offering of its euro-denominated notes maturing in January 2032 for a total principal amount of €400 million.

    The issue price of the notes was par, and the notes have a fixed rate coupon of 6.25% per annum. The notes are listed on The International Stock Exchange.

    The proceeds from the offering will be used to refinance existing debt of the group, including the redemption of existing senior secured notes due 2027, the repayment of amounts drawn under the existing revolving credit facility and certain local facilities, and the payment of related fees and expenses. Following completion of the refinancing, net leverage is expected to remain unchanged (excluding expenses in connection with the transaction). The transaction is consistent with the Group’s prudent financial policy and its approach of addressing upcoming debt maturities in advance. The successful offering reflects continued support from the Group’s bondholders and the strength of demand for United Group’s credit in the euro bond markets.

    This transaction follows the publication of United Group’s Q3 and nine-month 2025 results on 2 December 2025, which showed year-on-year growth in both revenue and adjusted EBITDAal and a further reduction in leverage. For the first nine months of 2025, revenue increased by 3% year-on-year to approximately €2.0 billion and Adjusted EBITDAal grew by 7% to approximately €680 million, with last-twelve-month revenue reaching €2.7 billion (up 4% year-on-year) and last-twelve-month Adjusted EBITDAal €909 million (up 9% year-on-year). As at 30 September 2025, net leverage based on last two quarters annualised Adjusted EBITDAal decreased to 4.3x, compared to 4.7x as at 30 June 2025, while gross leverage based on last two quarters annualised Adjusted EBITDAal decreased to 4.4x, from 4.8x over the same period.

    Stan Miller, CEO of United Group, said:

    “This successful transaction is a further vote of confidence from our bond investors and a natural next step following our strong Q3 and nine-month results. It allows us to continue our prudent approach to managing the capital structure, while we remain focused on executing our strategy in our core EU markets and maintaining the positive momentum in the business.”

    J.P. Morgan acted as global coordinator and physical bookrunner. BNP Paribas, Citigroup, Crédit Agricole CIB, Deutsche Bank, Goldman Sachs, ING, KKR, Mizuho, Morgan Stanley, Raiffeisen Bank International and UniCredit acted as joint global coordinators and bookrunners.

     

    Continue Reading

  • Elanco Investor Day Defines New Era as Sustainable Growth Company

    Elanco Investor Day Defines New Era as Sustainable Growth Company

    • Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.
    • Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from ‘Big 6’ blockbuster potential products by 2028.
    • Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms contributing to next wave innovation pipeline: monoclonal antibody discovery and immuno-therapeutics.
    • Announces intended closure of German animal R&D facility and targeted reduction to manufacturing workforce along with increased investment in Elanco Innovation Laboratories at its Indiana headquarters and continued investments in U.S. manufacturing as we have greater clarity on U.S. tariffs and accelerated USDA regulatory timelines. This includes an accelerated conditional approval pathway for a potential first-in-class immuno-therapeutic major pet blockbuster, expected in the next 2-3 years.
    • Announces technical sections complete for Befrena™ (tirnovetmab), the company’s IL-31 injectable monoclonal antibody for canine dermatitis, with expected differentiation in efficacy, convenience and value. Remains cautiously optimistic that administrative review and approval will be complete in Q4 2025.
    • Expects $200 to $250 million in adjusted EBITDA savings from Elanco Ascend by 2030.
    • Announces restructuring as part of Elanco Ascend to support margin expansion, optimize footprint and further increase innovation capacity. Creates an expected restructuring charge of approximately $175 million, of which approximately $130 million is expected to be cash-based costs. Expects savings of approximately $25 million in 2026 and approximately $60 million in 2027. 
    • Reaffirms Q4 and full year 2025 revenue and adjusted earnings guidance.

    INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ — Elanco Animal Health Incorporated (NYSE: ELAN) hosts its first Investor Day in five years this morning, marking a pivotal moment as the company further defines its new era of sustainable growth and long-term value creation. Elanco will detail how its consistent Innovation, Portfolio and Productivity (IPP) strategy is designed to guide the company’s transformation to a sustainable growth company, delivering consistent mid-single digit organic constant currency revenue growth and adjusted EBITDA margin expansion, while further strengthening its balance sheet and accelerating cash flow.

    “Today is a pivotal day for Elanco. We stand as a stronger Elanco ready for our next chapter as a sustainable growth company,” said Jeff Simmons, President and CEO at Elanco. “As we outline our financial outlook for the next three years, we are poised for significant growth. Our IPP strategy is delivering, our innovation engine is stronger than ever, and our team has built deep, lasting customer relationships that reinforce our confidence in our ability to win in the animal health market. Elanco is well-positioned to continue transforming, building a future where we expand our leadership and achieve consistent, reliable delivery against our priorities of growth, innovation and cash. We will bring high-impact innovation to customers – ultimately driving sustainable shareholder value while making life better for animals and the people who care for them.”

    Financial Outlook for Consistent Growth
    Elanco will outline a new three-year financial outlook with the expected annual results beginning in 2026, underscoring the company’s confidence in delivering strong, consistent performance:

    • Revenue Growth: Mid-single digit organic constant currency
    • Adjusted EBITDA Growth: High single digit
    • Adjusted EPS Growth: Low double digit
    • Free Cash Flow: At least $1 billion over the period from 2026 through 2028
    • Net Leverage Ratio: Achieving <3x in 2027, with a long-term target of 2.0x to 2.5x

    American Investment Driven by Tax, Tariff and Regulatory Clarity
    Elanco today announces continued investment in its U.S. operations, workforce and communities over the next five years. This investment deepens Elanco’s commitment to product innovation, advanced manufacturing and its customers – farmers, veterinarians and pet owners. The company will expand its R&D presence in its new Indianapolis global headquarters and surrounding OneHealth Innovation District, while continuing to invest in its U.S.-based manufacturing footprint. Elanco will further invest in its Kansas monoclonal antibody (mAb) manufacturing facility to support innovation, particularly a major next generation immuno-therapeutic pet innovation. The U.S. Department of Agriculture (USDA) has granted an accelerated pathway for conditional approval of a novel immuno-therapeutic that has the potential to be a first-in-class major pet health blockbuster, expected in the next 2-3 years.

    Additionally, as part of the positive engagement with the USDA, Elanco announces significant progress in the final steps of the approval of Befrena™, its newest potential blockbuster product. Review of all technical sections and label alignment is now complete, with the final administrative review underway at the USDA. Befrena has demonstrated differentiated efficacy in treating dogs with allergic dermatitis and canine atopic dermatitis. In both laboratory and field studies, Befrena has shown to be safe and well-tolerated, offering a dependable treatment option for veterinary professionals and pet owners alike. Befrena will offer important efficacy, convenience and value differentiators. Elanco continues to expect a first half 2026 launch.

    In connection with these investments, Elanco expects the 2026 net tariff impact to be immaterial to adjusted EBITDA growth, given additional tariff clarity and a positive offset from an incremental price increase.

    The combination of a favorable tax environment from the One Big Beautiful Bill Act, regulatory reform resulting in improved timelines for USDA regulatory reviews and greater certainty on tariffs has created favorable conditions for the continuation of U.S. investments in R&D and manufacturing, while bringing key innovation capabilities from Europe to the U.S.

    Innovation: Delivering a Consistent Flow of High-Impact Innovation
    Since defining its basket of innovation in December 2020, Elanco has repeatedly raised the bar on its innovation target. Elanco now expects this innovation to generate approximately $1.1 billion in revenue in 2026, an increase of over $200 million from $840 to $880 million expected in 2025. 

    Looking ahead at Elanco’s next wave of innovation, the company has increased its target innovation areas to eight and added two new major internal development platforms with monoclonal antibodies (mAbs) and immunotherapy. Elanco has 10+ major innovation projects with blockbuster potential in development, expecting approvals for 5-6 major differentiated assets from this pipeline between 2026 and 2031. These differentiated pipeline assets represent an unprobabilized potential peak sales value of more than $2 billion – effectively doubling the value of the last wave.

    “Over the past several years, Elanco has created a one-of-a-kind innovation powerhouse that has maximized capacity and throughput, delivering a continuous flow of differentiated products,” said Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco. “There are more projects and more value in the pipeline than ever, and we’ve added cutting edge in house monoclonal and immunotherapy technology development platforms. We will continue to invest in the capacity and capabilities to bring new solutions to market that help pets live heathier, more active, longer lives and help farmers improve animal health, welfare and sustainability.”

    Diverse Market-Leading Portfolio: Positioned for Sustained Growth
    Elanco is innovating in large, growing markets, supported by a strong, diverse portfolio. This includes leading growth in U.S. Pet Health and #1 positions in global pet retail and poultry, U.S. beef and swine. Elanco expects to double revenue from its ‘Big 6’ potential blockbuster products from 2025 to 2028 as it globalizes this basket of innovation (AdTab™, Befrena, Bovaer®, Credelio Quattro™, Experior®, Zenrelia™).

    Productivity: Driving Margin Expansion and Free Cash Flow
    Elanco’s commitment to operational excellence and financial discipline is a cornerstone of its strategy, with a clear path to expanding margins, improving free cash flow and becoming a simpler, more efficient company. The company anticipates meaningful adjusted EBITDA improvement with high single-digit percentage growth, and free cash flow generation increasing through the period.

    Elanco is also announcing organizational changes designed to generate approximately $25 million and $60 million in savings in 2026 and 2027, respectively, as part of its Elanco Ascend productivity initiative.

    These strategic adjustments include:

    • Transforming and Investing in Innovation: A larger, more complex pipeline requires more capacity, new technical capabilities and increased investment. As such, Elanco is expanding its R&D organization in Indianapolis, refining its regulatory structure and proposing the closure of its Germany animal facility. The company also announces a strategic partnership with The Clinglobal Group to substantially expand capacity and capabilities, while being significantly more cost effective.
    • Optimizing Manufacturing Footprint: Elanco will continue to optimize its manufacturing footprint to power its pipeline, adjust to future volume expectations and continue the organization’s productivity journey, including reducing workforce in higher-cost locations.

    Approximately 600 roles will be impacted across Elanco with 300 eliminated positions and 300 shifted to other areas or locations. The company expects a charge of approximately $175 million, of which about $130 million is expected to be cash based.

    In total, the company expects its Elanco Ascend program to deliver $200 to $250 million in adjusted EBITDA savings by 2030, with about 30% achieved in 2026.

    “Our goal is clear: consistent, reliable delivery,” said Bob VanHimbergen, Executive Vice President and CFO at Elanco. “We are taking the steps needed to become a more efficient, productive company, ensuring our resources are in the right places to fuel our no-regrets launches and invest in our pipeline while deleveraging and delivering on adjusted EBITDA margin growth. As we move into the second half of the decade, Elanco expects to deliver durable, profitable growth and sustained cash generation while creating lasting value for shareholders.

    In conjunction with today’s event, Elanco is reaffirming its fourth quarter and fiscal 2025 outlook, provided on November 5, 2025, other than reported net loss and net loss per share, which will be impacted by the aforementioned restructuring charges.

    WEBCAST
    Elanco will host a webcast from approximately 9 a.m. to 12 p.m. Eastern Time today, featuring presentations from Elanco’s senior leadership team on the company’s strategic priorities, financial outlook and innovation pipeline – defining Elanco’s new era as a sustainable growth company. Access to the live webcast and related materials is available on Elanco’s Investor Events and Presentations website. A replay will be available on the website following the event.

    ABOUT ELANCO
    Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

    CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and fourth quarter guidance and long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

    Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following:

    • operating in a highly competitive industry;
    • the success of our research and development (R&D), regulatory approval and licensing efforts;
    • the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;
    • competition from generic products that may be viewed as more cost-effective;
    • changes in regulatory restrictions on the use of antibiotics in farm animals;
    • an outbreak of infectious disease carried by farm animals;
    • risks related to the evaluation of animals;
    • consolidation of our customers and distributors;
    • the impact of increased or decreased sales into our distribution channels resulting in fluctuations in our revenues;
    • our dependence on the success of our top products;
    • our ability to complete acquisitions and divestitures and to successfully integrate the businesses we acquire;
    • our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;
    • manufacturing problems and capacity imbalances, including at our contract manufacturers;
    • fluctuations in inventory levels in our distribution channels;
    • risks related to the use of artificial intelligence in our business;
    • our dependence on sophisticated information technology systems and infrastructure, including the use of third-party, cloud-based technologies, and the impact of outages or breaches of the information technology systems and infrastructure we rely on;
    • the impact of weather conditions, including those related to climate change, and the availability of natural resources;
    • demand, supply and operational challenges associated with the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern;
    • the loss of key personnel or highly skilled employees;
    • adverse effects of labor disputes, strikes and/or work stoppages;
    • the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that limit our operating flexibility and changes in our credit ratings that lead to higher borrowing expenses and restrict access to credit;
    • changes in interest rates that adversely affect our earnings and cash flows;
    • risks related to the write-down of goodwill or identifiable intangible assets;
    • the lack of availability or significant increases in the cost of raw materials;
    • risks related to foreign and domestic economic, political, legal and business environments;
    • risks related to foreign currency exchange rate fluctuations;
    • risks related to underfunded pension plan liabilities;
    • our current plan not to pay dividends and restrictions on our ability to pay dividends;
    • the potential impact that actions by activist shareholders could have on the pursuit of our business strategies;
    • risks related to tax expense or exposures;
    • actions by regulatory bodies, including as a result of their interpretation of studies on product safety;
    • the possible slowing or cessation of acceptance and/or adoption of our farm animal sustainability initiatives;
    • the impact of increased regulation or decreased governmental financial support related to the raising, processing or consumption of farm animals;
    • risks related to tariffs, trade protection measures or other modifications of foreign trade policy;
    • the impact of litigation, regulatory investigations and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters;
    • challenges to our intellectual property rights or our alleged violation of rights of others;
    • misuse, off-label or counterfeiting use of our products;
    • unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products;
    • insufficient insurance coverage against hazards and claims;
    • compliance with privacy laws and security of information;
    • risks related to environmental, health and safety laws and regulations; and
    • inability to achieve goals or meet expectations of stakeholders with respect to environmental, social and governance matters.

    For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company’s latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this press release. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this press release. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data.

    Use of Non-GAAP Financial Measures

    This press release contains forward-looking non-GAAP financial measures, such as organic constant currency revenue growth, adjusted EBITDA growth, adjusted EPS growth, free cash flow and net debt leverage. We have not provided related GAAP financial measures for forward-looking non-GAAP financial measures because we are unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items, such as restructuring and certain non-cash items, which could significantly impact our GAAP results. These non-GAAP measures are not, and should not be viewed as, substitutes for GAAP reported measures.

    Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]
    Media Contact: Colleen Parr Dekker (317) 989-7011 [email protected]

    SOURCE Elanco Animal Health

    Continue Reading

  • Falsified SIMULECT (basiliximab) for injection

    Falsified SIMULECT (basiliximab) for injection

    Alert Summary

    This WHO Medical Product Alert refers to falsified SIMULECT (basiliximab) for injection. The falsified product has been detected in Rwanda, Bulgaria, and Türkiye, and was reported to the WHO in December 2024 and November 2025.

    SIMULECT (basiliximab) is an immunosuppressant medicine classified as a monoclonal antibody. It is indicated for the prevention of acute organ rejection in adults and children undergoing kidney transplantation. SIMULECT is supplied as a powder vial with or without a water for injection (solvent) ampoule for reconstitution, and is administered either as an intravenous infusion or as an injection, usually in a hospital setting.

    How to identify the falsified product

    This product is falsified because it deliberately misrepresents its identity, composition, and source. The genuine manufacturer has confirmed that the products listed in this alert are falsified. A sample of the falsified product was forensically tested by the genuine manufacturer and found to contain no active pharmaceutical ingredients; instead, it contained ascorbic acid. The genuine manufacturer also identified several visual discrepancies on the packaging:

    Batch number: The falsified product shows batch number SFYD2, which is not a valid batch number for SIMULECT. Any SIMULECT product with batch number SFYD2 should be considered falsified.

    Folding box and label information: The falsified product label displays the National Drug Code NDC 0078-0331-84. While the National Drug Code (NDC) is a unique identifier for medicines marketed in the United States of America, the label contains other discrepancies compared to genuine SIMULECT packaging.

    • The genuine product lists the ingredient dose in milligrams using “mg,” while the falsified product uses “MG”.
    • The genuine product lists the country of manufacture as “Product of France” while the falsified product lists the country of manufacture as “Product of Switzerland or France”.

    Risks

    This falsified product should be considered unsafe, and its use may pose severe and potentially life-threatening risks to patients, including:

    • Therapeutic failure leading to organ rejection.
    • Inadequate or excessive immune suppression, increasing vulnerability to opportunistic infections.
    • Life-threatening allergic or toxic reactions from unknown or harmful ingredients.
    • Risk of infection from unsterile injections.

    It is important to detect and remove any falsified SIMULECT from circulation to prevent harm to patients.

    Advice to health-care professionals, regulatory authorities, and the public

    Health-care professionals should report any unexpected adverse reactions, lack of therapeutic effects, or quality defects to their National Regulatory Authorities or National Pharmacovigilance Centre.

    WHO advises increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these falsified products. Increased surveillance of the informal/unregulated market, including online platforms is also advised. National regulatory authorities/health authorities/law enforcement are advised to immediately notify WHO if the falsified product is detected in their country. If you are in possession of this product, WHO recommends that you do not use it. If you, or someone you know, has, or may have used these products, or suffered an adverse event or unexpected side-effect after use, seek immediate medical advice from a health-care professional or contact a poisons control centre.

    All medical products must be obtained from authorized/licensed suppliers. If you have any information about the manufacture or supply of these falsified products, please contact WHO via rapidalert@who.int.

    Annex: Product subject of WHO Medical Product Alert N°6/2025

     

     

     

     

     

     

    Continue Reading

  • Siemens and nVent to release joint reference architecture purpose-built for NVIDIA AI data centers | Press | Company

    Siemens and nVent to release joint reference architecture purpose-built for NVIDIA AI data centers | Press | Company

    [{“nid”:0,”name”:”Products & Solutions”,”tid”:0,”url_str”:”https://www.siemens.com/global/en/products.html”,”alias”:”https://www.siemens.com/global/en/products.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“nid”:0,”name”:”Industries”,”tid”:1,”url_str”:”https://xcelerator.siemens.com/global/en/industries.html”,”alias”:”https://xcelerator.siemens.com/global/en/industries.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“nid”:0,”name”:”Company”,”tid”:2,”url_str”:”https://www.siemens.com/global/en/company.html”,”alias”:”https://www.siemens.com/global/en/company.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]}]

    Continue Reading

  • Plug to Participate in Wells Fargo Energy & Power Conference – ir.plugpower.com

    1. Plug to Participate in Wells Fargo Energy & Power Conference  ir.plugpower.com
    2. Plug to Participate in the Asia-Pacific Investor Call with J.P. Morgan  Yahoo Finance
    3. Plug Power executives to attend two investor conferences in NYC By Investing.com  Investing.com
    4. Plug Power Inc. to Participate in Asia-Pacific Investor Conference Discussing Hydrogen Strategy and Growth Opportunities  Quiver Quantitative

    Continue Reading

  • Fosun Pharma’s Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

    SHANGHAI, Dec. 9, 2025 /PRNewswire/ — Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (“Yao Pharma”), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient. The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use. Under the terms of the agreement, Yao Pharma will complete an ongoing YP05002 Phase 1 clinical trial in Australia and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide. Yao Pharma will receive an upfront payment of $150 million and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.935 billion, as well as tiered royalties on sales, if approved.

    The licensed small-molecule GLP-1R agonists were independently researched and developed by Fosun Pharma’s subsidiary Yao Pharma with proprietary intellectual property rights and are intended for the treatment of metabolic diseases, with potential indications including but not limited to chronic weight management, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), among others. YP05002 is currently in Phase 1 clinical development in Australia.

    “The partnership with Pfizer marks the international recognition of Yao pharma’s R&D capabilities. We firmly believe that only through openness and collaboration can the value of innovation be maximized.” Mr. Liu Qiang, Chairman of Yao Pharma, stated, “Leveraging Pfizer’s exceptional global development experience and commercialization network, along with Yao Pharma’s profound expertise in small molecule R&D and manufacturing, our shared goal is to enable this innovative drug candidate to be developed and commercialized in order to benefit patients worldwide more quickly and broadly.”

    “The global collaboration with Pfizer is another significant milestone in Fosun Pharma’s strategy of innovation and internationalization.” Mr. Chen Yuqing, Chairman of Fosun Pharma, said, “Fosun Pharma is committed to addressing unmet clinical needs. We look forward to working with Pfizer to expedite the global development and commercialization of YP05002, with the goal of working toward addressing the challenges of obesity and metabolic diseases for patients in need.”

    SOURCE Fosun Pharma

    Continue Reading

  • Microsoft to invest more than $5.4 billion in Canada to boost AI infrastructure – Reuters

    1. Microsoft to invest more than $5.4 billion in Canada to boost AI infrastructure  Reuters
    2. Microsoft vows to protect ‘digital sovereignty’ in $7.5-billion Canadian data-centre expansion  The Globe and Mail
    3. Microsoft – Microsoft Deepens Its Commitment To Canada With Landmark $19B Ai Investment – Blog  TradingView
    4. Microsoft to invest more than $5 billion in Canada over next two years  Yahoo! Finance Canada
    5. Microsoft deepens its commitment to Canada with landmark $19B AI investment – blog  marketscreener.com

    Continue Reading

  • China’s Hydrogen Industry – Opportunities for Foreign Investors

    China’s Hydrogen Industry – Opportunities for Foreign Investors

    China’s hydrogen industry is poised for major growth as the country intensifies the development of infrastructure and promotes end-use applications as a low-carbon fuel. In its current form, however, the industry is still heavily reliant on fossil fuels, and the green hydrogen segment is still in its infancy. These realities present both exciting opportunities for early investments and intrinsic early-mover risks, as infrastructure and value chains remain immature and future demand growth is uncertain. Foreign investors can seek to capitalize on the country’s bet on the emerging fuel source by selecting strategic and limited entry points and exploring the scope of possibilities.


    China is doubling down on its bet on hydrogen as a potentially revolutionary clean energy source. Viewed as a means of diversifying the country’s energy mix and bolstering energy security, the clean-burning fuel may also prove key to decarbonizing hard-to-abate sectors such as transportation, steel, and chemicals. But as in the rest of the world, current production and utilization of hydrogen remain closely tied to the petrochemicals and coal industries. Most hydrogen is currently produced from fossil fuels, and its use is still concentrated in refinery, petrochemicals, and other energy-intensive industrial processes. 

    China’s green hydrogen industry is still in its infancy, both in terms of large-scale production and diversified end-use applications. Due to its significant potential as a low-carbon energy source, the sector nonetheless enjoys strong government attention and support. It has been outlined as one of six “future industries” (along with nuclear fusion energy) of focus for the 15th Five-Year Plan period (2026 to 2030). This creates meaningful potential for future technological development, expanded adoption, and access to government incentives as the sector grows. 

    Against this backdrop, opportunities for foreign investment emerge across multiple segments of the hydrogen value chain. Potential entry points range from production technologies and equipment to storage and transport solutions, to downstream applications in transportation, industrial heating, and chemical processing. These openings reflect both the scale of China’s future hydrogen ambitions and the ongoing need for advanced technologies, high-quality equipment, and operational expertise as the industry evolves.

    Explore vital economic, geographic, and regulatory insights for business investors, managers, or expats to navigate China’s business landscape. Our Online Business Guides offer explainer articles, news, useful tools, and videos from on-the-ground advisors who contribute to the Doing Business in China knowledge.
    Start exploring

    Overview of China’s hydrogen industry 

    Hydrogen production 

    China is the world’s leading producer of hydrogen. In 2024, total hydrogen output grew 3.5 percent year-on-year to 36.5 million metric tons, according to the National Energy Administration (NEA), accounting for over a third of global production.

    As is the case worldwide, China’s hydrogen production is primarily based on the coal and petrochemical industries. The majority of hydrogen in China is the so-called “black” or “brown” hydrogen, which comes from coal, a high-emitting source most commonly produced through the process of gasification. According to the NEA, around 56 percent of China’s total hydrogen production came from coal and 21 percent from natural gas. A further 21 percent was produced as an industry by-product (usually from the petrochemical industry). Only around 1 percent was produced through electrolysis, the process of using electricity to split water into oxygen and hydrogen, which, if produced using renewable energy sources, is the cleanest form of hydrogen. 

    This proportion aligns with global production trends. According to the International Energy Agency (IEA), less than 1 percent of global hydrogen production in 2024 came from low-emissions sources. 

    Hydrogen production in China is primarily concentrated in the north and northwest, with the provinces of Shandong, Inner Mongolia, Shaanxi, Ningxia, and Shanxi together accounting for 45 percent of total output in 2024. 

    Hydrogen utilization 

    According to NEA data, in 2024, over half of China’s hydrogen – a combined 53 percent – was used in the methanol and ammonia synthesis industries, while the refinery industry consumed 16 percent and the coal chemical industry 11 percent. The remaining 20 percent was utilized in industries such as transportation, heating, and metallurgy. 

    chart visualization

    As with production, hydrogen consumption is mainly concentrated in traditional heavy industrial provinces such as Shandong, Inner Mongolia, Shaanxi, Ningxia, and Shanxi. 

    Green hydrogen projects 

    While green hydrogen accounts for just a small proportion of China’s overall hydrogen production, the country is expanding output capacity, in particular in areas with rich renewable energy resources. 

    According to the NEA, there were over 600 planned renewable energy hydrogen electrolysis projects at the end of 2024, of which 94 had been completed, and a further 83 were under construction. The current output of the completed green hydrogen projects at the end of 2024 was 125,000 tonnes per year. Northern and northwestern China account for around 45 percent and 44 percent of this capacity, respectively, driven by these regions’ strong traditional industrial bases and rich renewable resources.

    Find Business Support

    2024 alone saw the completion of 35 new green hydrogen products with a combined output capacity of 48,000 tonnes per year. This was an increase of 62 percent in newly added capacity from the previous year. The main downstream uses of this green hydrogen were transport, oil refinery, and ammonia and methanol synthesis, as well as metallurgy, heating, power generation, energy storage, and scientific research. 

    China’s total green hydrogen capacity may see yet another increase in 2025, with the government actively funding a number of green hydrogen demonstration projects. In April 2025, the National Development and Reform Commission (NDRC) included nine green hydrogen projects in a list of advanced green and low-carbon technology demonstration projects, which will receive government investment. The projects, which cover the production, storage, and transmission of green hydrogen, among other processes, are primarily located in Inner Mongolia, Ningxia, Jiangsu, Tianjin, and Xinjiang. 

    According to a recent report from the Centre for Research on Energy and Clean Air (CREA), the combined capacity of the electrolyzers of these nine projects is 5.9GW  – seven times the capacity of the green hydrogen projects included on the 2024 list. 

    Transportation and fuel cell vehicles 

    As in the rest of the world, China’s hydrogen fuel cell vehicle (FCV) industry is still in its infancy. According to data from the China Association of Automobile Manufacturers (CAAM) cited by the media, between 2015 and 2024, a total of 24,042 FCVs had been produced in China and 23,501 sold. In 2024, only 5,548 FCVs were manufactured, a year-on-year decline of 10.4 percent. FCV sales were similarly low, with just 5,405 sold, falling 12.6 percent from 2023. 

    The industry appears to have fared no better in 2025; CAAM data shows that in the first six months of the year, only 1,364 hydrogen FCVs were produced, a drop of 47.2 percent year-on-year, and only 1,373 were sold, down 46.8 percent year-on-year.  

    As the data shows, the industry has not taken off as quickly as hoped. A key hydrogen development plan released by the National Development and Reform Commission (NDRC) in 2022 targeted for China to have a fleet of around 50,000 hydrogen FCVs by 2025 – a figure it appears unlikely to reach. The slow uptake is due in part to the limited production and supportive infrastructure, such as refueling stations, which hamper widespread production and adoption. According to the NEA, there were around 540 hydrogen refueling stations at the end of 2024. 

    The NEA nonetheless notes key technological breakthroughs in the deployment of hydrogen and hydrogen-derived fuels for transport in recent years. These include a long-haul hydrogen-powered logistics trial on the Beijing–Shanghai expressway, the rollout of a 2,400-kW hydrogen-powered train, and the first flight of a prototype light hydrogen-combustion aircraft. Progress has also extended to maritime applications, with the methanol-fueled vessel Guoneng Yangtze 01 entering commercial operations, a 5,500-horsepower ammonia-fueled tugboat completing marine ammonia bunkering, and a large methanol-powered container ship carrying out ship-to-ship refueling.  

    Policy landscape 

    In 2022, the NDRC released the Medium- and Long-Term Development Plan for the Hydrogen Energy Industry (2021-2035) (the “2021 to 2030 Development Plan), which sets targets and provides policy guidance for the industry’s development.

    Find Business Support

    This plan called hydrogen energy “an important component of the future national energy system” and a “crucial conveyor for achieving the green and low-carbon transition in energy end uses”, underscoring how the government views the technology as an important tool for both national energy security and decarbonization. 

    Over the past few years, the Chinese government has elevated the hydrogen industry as one of the “future industries” with significant potential for expansion and application. The 14th Five-Year Plan (the national development plan for the period from 2021 to 2025) called for the government to “organize and implement future industry incubation and acceleration programs, and plan and deploy a number of future industries”, which included hydrogen energy and energy storage. 

    The sector was also mentioned in the proposals for the 15th Five-Year Plan, released at the end of October 2025, which acts as the blueprint for the finalized plan, which will be implemented in 2026. It specifically calls for “proactively planning for future industries, exploring a variety of technological routes, typical application scenarios, feasible business models, and market regulatory rules to promote […] hydrogen energy”, among other emerging sectors, and to “innovate regulatory methods, develop venture capital, and establish mechanisms for increasing investment and sharing risks in [these] future industries”. 

    Key development targets 

    The 2021 to 2030 Development Plan sets a series of five-, 10-, and 15-year goals for the development of hydrogen production and adoption. However, it only sets numerical targets for 2025, namely:

    • Have a fleet of around 50,000 fuel cell vehicles in operation and deploy and construct “a batch” of hydrogen refueling stations. 
    • Increase renewable energy hydrogen production to 100,000 to 200,000 tonnes/year, reducing carbon dioxide emissions by 1 to 2 million tonnes/year. 

    By 2030, China will strive to have formed “a relatively complete hydrogen energy industry technology innovation system and clean energy hydrogen production and supply system, with a rational and orderly industrial layout. Renewable energy hydrogen production will be widely applied, strongly supporting the achievement of the [2030] carbon peak target”. 

    By 2035, “a hydrogen energy industry system will be formed”, supporting a diversified hydrogen energy application ecosystem that covers transportation, energy storage, and industry. Additionally, the proportion of hydrogen from renewable energy sources in final energy consumption will have “increased significantly” and will play “an important supporting role in the green transformation and development of energy”. 

    Development and adoption of green hydrogen 

    At the end of 2024, the Ministry of Industry and Information Technology (MIIT) released the Implementation Plan for Accelerating the Application of Clean and Low-Carbon Hydrogen in Industrial Sectors (the “Green Hydrogen Implementation Plan”), which builds on the 2021 to 2030 Development Plan to set more granular targets and policy outlines for the production and utilization of green hydrogen. 

    The Green Hydrogen Implementation Plan’s core aim is to achieve significant progress in “supporting equipment and promoting technologies for clean and low-carbon hydrogen applications in the industrial sector” by the year 2027. It highlights key industries for application, including metallurgy, synthetic ammonia, synthetic methanol, and oil refinery. It also calls for deploying demonstration applications in fields such as industrial green microgrids, shipping, aviation, and rail transportation, and to create commercial application models for hydrogen energy in transportation, power generation, and energy storage.  

    Opportunities for foreign investors in China’s hydrogen industry

    For foreign investors, China’s hydrogen sector offers a combination of challenges and opportunities. While it is a nascent industry with considerable room for growth, many viable applications and benefits of the technology have already been proven across multiple fields. The sector also has strong policy backing and an expectation of rising demand as technologies mature and costs decline. At the same time, early movers face clear risks, from underdeveloped infrastructure and evolving standards to potential setbacks associated with the commercialization of emerging technologies.  

    Despite these challenges, the outlook of China’s hydrogen industry is compelling, and the Chinese government continues to spotlight a number of hydrogen-related segments as priority areas for development. Additionally, the 2022 edition of the Catalogue of Encouraged Industries for Foreign Investment (the “2022 FI Encouraged Catalogue”) includes several fields related to hydrogen energy, including FCVs, equipment manufacturing, and technology R&D. 

    Equipment manufacturing and technology development 

    Equipment manufacturing remains a strong area of opportunity for foreign investors, particularly as China works to build out the full hydrogen value chain. The 2022 FI Encouraged Catalogue includes green hydrogen production technologies, such as hydrogen from chemical by-products, biological hydrogen production, and renewable-energy-based electrolysis, as well as hydrogen storage, transportation, and liquefaction. This reflects broad openness to foreign firms engaged in the core technologies required to produce and handle hydrogen at scale. 

    Foreign companies with advanced manufacturing expertise and proprietary technologies can find demand across multiple equipment categories. These include electrolyzers, membrane and catalyst materials, compressors, high-pressure storage systems, liquid hydrogen equipment, and purification and transport systems. 

    In addition, opportunities exist in upstream technology development. As China seeks to expand green hydrogen production and improve the performance of production and storage systems, companies offering innovations in electrolysis efficiency, materials science, and modular system design are well-positioned to collaborate with local partners or establish localized manufacturing. For foreign investors, this segment offers a pathway to participate in China’s emerging hydrogen ecosystem while contributing high-value technologies and capabilities. 

    Hydrogen FCVs 

    One tangible opportunity for foreign investors in the hydrogen industry is the development of hydrogen FCVs. Although the industry has faced setbacks in recent years, continuous policy support means there is still a strong possibility for the market’s future growth. 

    China has identified hydrogen-powered transportation as a strategic growth area, offering both policy support and a clear roadmap for industry development. The 2022 FI Encouraged Catalogue explicitly includes several activities related to FCVs. These include the design and R&D of hydrogen fuel cell power systems, the construction and operation of hydrogen refueling stations, and the development, manufacturing, and operation of new energy storage equipment, including hydrogen storage.

    Find Business Support

    Policy directives outlined in the Green Hydrogen Implementation Plan further reinforce these opportunities. The plan emphasizes technological innovation in fuel cells and hydrogen storage, encouraging the development of high-power, efficient, and long-life fuel cells, high-efficiency hydrogen or ammonia internal combustion engines, and high-pressure, high-density onboard hydrogen storage systems.  

    Demonstration projects are also being encouraged to integrate renewable hydrogen and high-quality industrial by-product hydrogen, supporting distributed hydrogen production and refueling stations. Simultaneously, the scale-up of FCV use in industrial clusters, such as industrial parks, logistics hubs, ports, and mines, is a priority, creating opportunities for foreign companies to supply vehicles, refueling infrastructure, fleet management systems, and operational expertise. The government also supports the creation of “district-to-district” hydrogen energy logistics corridors and city clusters for fuel cell vehicle demonstrations, while initiatives such as “Hydrogen for All” promote applications across highways, ports, industrial zones, and commercial equipment, further opening avenues for technology deployment and commercialization. 

    Investors should nonetheless be aware of the risks associated with entering an immature industry. China’s hydrogen FCV industry has stagnated, despite government support for pilot projects. The sector continues to suffer from high costs for fuel cells and refueling stations, the limited number and inconvenient locations of refueling stations, and the high price of hydrogen due to limited supply.  

    For this reason, foreign investors should approach the market with caution, prioritizing cost reduction strategies, such as utilizing lower-cost black or brown hydrogen in the short term and focusing initially on applications that may be easier to commercialize, such as trucks and freight transport, rather than passenger vehicles. Investors may also look at the construction and operation of hydrogen fueling stations, as well as R&D and manufacturing of hydrogen FCV components such as hydrogen circulation pumps, hydrogen ejectors, 70MPa hydrogen cylinders, and vehicle-mounted hydrogen concentration sensors, all of which are listed in the 2022 FI Encouraged Catalog. 

    At the same time, policy incentives will remain critical to industry growth, making it essential for investors to closely monitor evolving government support and align market entry or expansion plans accordingly. 

    Clean and low-carbon hydrogen alternatives 

    China is placing strong emphasis on replacing fossil-fuel-based hydrogen with cleaner alternatives across its industrial system, creating a range of opportunities for foreign technology providers and project developers.  

    Related Reading

    The Green Hydrogen Implementation Plan promotes several areas for development in this field. First, major energy- and materials-intensive sectors, such as refining, petrochemicals, coal chemicals, non-ferrous metals, semiconductors, and pharmaceuticals, are being encouraged to substitute conventional fossil-derived hydrogen with clean or low-carbon hydrogen. This shift is expected to generate demand for advanced electrolysis technologies, hydrogen purification systems, and equipment that can be integrated into existing production lines. 

    Second, authorities are prioritizing the development of low-cost renewable-energy-based hydrogen production. This includes advancing “solar + storage” solutions, promoting integrated “hydrogen production + hydrogen use” projects in regions rich in wind and solar resources, and supporting off-grid or weak-grid hydrogen production models. These initiatives open space for foreign firms with expertise in renewable integration, energy storage, and high-efficiency power electronics. 

    The plan also highlights frontier areas such as coupling industrial waste heat with high-temperature electrolysis and leveraging offshore wind for hydrogen production. In addition, China is encouraging the scaled-up purification of industrial by-product hydrogen and the installation of carbon capture, utilization, and storage (CCUS) systems at fossil-based hydrogen facilities, creating further opportunities for specialized equipment and engineering services. 

    A promising but uncertain future 

    China’s hydrogen industry presents a complex but promising landscape for foreign investors. On the demand side, hydrogen’s potential role in decarbonizing hard-to-abate sectors positions it as a strategic future energy source with significant long-term growth prospects. This potential is further reinforced by strong government backing, with hydrogen repeatedly identified as a priority emerging industry and a focus of national development planning. These factors create a potentially favorable environment for foreign participation across multiple segments of the value chain. 

    At the same time, the industry’s immaturity poses inherent risks. Production, infrastructure, and end-use applications are still developing, and recent years have shown that market growth can be slower and more uneven than expected. For this reason, investors should adopt a cautious and selective approach, targeting segments where early commercial opportunities exist, limiting exposure in areas facing high uncertainty, and aligning closely with evolving policy incentives. 

    About Us

    China Briefing is one of five regional Asia Briefing publications. It is supported by Dezan Shira & Associates, a pan-Asia, multi-disciplinary professional services firm that assists foreign investors throughout Asia, including through offices in Beijing, Tianjin, Dalian, Qingdao, Shanghai, Hangzhou, Ningbo, Suzhou, Guangzhou, Haikou, Zhongshan, Shenzhen, and Hong Kong in China. Dezan Shira & Associates also maintains offices or has alliance partners assisting foreign investors in Vietnam, Indonesia, Singapore, India, Malaysia, Mongolia, Dubai (UAE), Japan, South Korea, Nepal, The Philippines, Sri Lanka, Thailand, Italy, Germany, Bangladesh, Australia, United States, and United Kingdom and Ireland.

    For a complimentary subscription to China Briefing’s content products, please click here. For support with establishing a business in China or for assistance in analyzing and entering markets, please contact the firm at china@dezshira.com or visit our website at www.dezshira.com.

     

    Continue Reading

  • IHG’s Christophe Laure on the next era of the Intercontinental and luxury hotel growth

    IHG’s Christophe Laure on the next era of the Intercontinental and luxury hotel growth

    As luxury hospitality grows into a $166bn (€142bn) global market, IHG’s new head of luxury and lifestyle, Christophe Laure, shares how Intercontinental Paris Le Grand is refining its approach to stay ahead in an…

    With 12 palace-level hotels and a reputation for the refined, Paris has long been a global benchmark for luxury stays. Among the most storied of its offerings is the Intercontinental Paris Le Grand, a landmark facing the Opéra Garnier. Behind its baroque façade, travellers with taste and locals looking for a well-appointed dining experience head to its Winter Garden and Café de la Paix. 

    For the past 15 years the hotel was managed by Christophe Laure, now newly appointed to lead all of Intercontinental Hotels Group’s (IHG) luxury and lifestyle properties. His promotion comes at a time when the sector is both fiercely competitive and continuing to see growth and expansion in the City of Light and beyond.

    Home front: Intercontinental Paris Le Grand façade (Image: Jérôme Galland)

    With an estimated value of $154.32bn (€132.5bn) in 2024, projections suggest the value of the global luxury hospitality sector will exceed $166bn (€142bn) before the end of 2025 and surpass $218bn (€187bn) by 2029. France is very much a key player in this growth. The French luxury-hospitality market was valued at approximately $12.16bn (€10.43bn) in 2024 and it is anticipated to grow at an average annual rate of 2.74 per cent through 2029.

    So how does one ensure that their property sees a decent chunk of change from this rise in luxury-hospitality stays? At a time when hotels are branching into experiences, sustainability initiatives, merchandise, fashion collaborations, wellness and heritage storytelling, there’s a lot for any hotelier to consider when trying to keep their establishment booked, profitable and relevant. As Laure tells Monocle, hotels such as the Intercontinental are refining their approaches to hospitality to mark themselves clearly as luxury players as opposed to the many high-end options. 

    In the calm of the grand glasshouse, Laure confides his plans for 2026, discusses the state of the luxury hospitality market and how the Intercontinental is matching evolved guest expectations. 

    Man for the moment: Christopher Laure (Image: Courtesy of Intercontinental Paris Le Grand)

    With the competition in the upper-luxury segment so tough in Paris at the moment, how does Intercontinental stand out?
    Our history is rooted in international travel and that remains our strength to this day. When Pan American World Airways was opening routes between North and South America in 1946, the CEO of Pan-Am told the president that [new hotels at the airline’s destinations] would live up to the standards of Pan-Am’s glorious cabins, and so the first Intercontinental hotel was born to provide quality and safe accommodation to the traveller crossing continents for business.

    How do you meet the specific needs of the clientele of upper-luxury travellers who are constantly on the move?
    This might seem obvious but the first thing that you need when you travel abroad is to feel safe and we take that very seriously. Then the key is attention to detail. When our customers walk into their room, we want them to feel that they are the first to ever stay there, that it’s brand new. Our clientele also cares about attentive service: always being there without seeming to, being present but discreet, along with high-quality cuisine, of course.

    Gold standard: The Intercontinental Paris Le Grand’s Salon Opéra (Image: Jérôme Galland)

    Are there markets where you find this is in especially high demand?
    Asia and the Middle East. The Middle East is a more mature market now; we have been there for about 30 years. But Asia – even though China is in the midst of a slowdown – is a market where there is a lot of interest in what we do. There is an eagerness there to discover and reproduce what we offer in France. I have a client who sent me some photos of a hotel where he was staying in Hanoi recently and the layout is remarkably similar to Le Grand Hotel’s. It’s flattering. 

    For a hotel group, what do you think is key to a successful international expansion?When you want to grow roots in a new market, you need to respect what the people there are used to consuming. But at the same time, put forward your own expertise and offer something new. 

    For example, IHG was one of the first groups to invest in China. Today we have 800 hotels there. There are properties from our global brands, such as Intercontinental, Kimpton and Crowne Plaza. But we also created a completely new brand, Hualuxe, which is a Chinese label dedicated to the Chinese market. This way everyone gets what they want. International travellers can rely on brands that they already know and love, and we show the domestic clientele that we are also attuned to their expectations. 

    State of the art: Café de la Paix (Image: Jérôme Galland)

    Looking ahead, what are the heavy trends that you see shaping hospitality?
    In short, the human side of it. Customers want to be recognised: they crave that empathy, that sense that we know who they are and what they need – how they like their breakfast, for instance – because they have stayed with us in the past and that’s how we keep them coming back. That’s not to say there isn’t a technological aspect to this human touch. We have the longest-running loyalty programme in the business and that has served us well. We also want to provide customers with the convenience of getting updates on their booking and their stay through an app. For our staff as well, we are investing heavily in technology to provide new tools that allow them to spend as much time as possible on personal interactions that really make the biggest difference in our business.

    Continue Reading

  • Lloyd’s Register and Latsco chart a new digital course for ship classification

    Lloyd’s Register and Latsco chart a new digital course for ship classification

    Lloyd’s Register (LR) and Latsco have successfully completed a proof-of-concept for a new standard in digital class assurance with data-driven surveys.  

    This collaboration aims to demonstrate how verified operational vessel data can fully meet class survey requirements, without compromising safety, integrity, or technical rigour.  

    The proof-of-concept was conducted on the vessel HELLAS MARGARITA during an active voyage to Singapore. Using LR’s approved Digital Survey Test Procedure, the project team remotely tested, recorded and verified the vessel’s auxiliary engine alarms, controls, shutdowns and safety systems through raw data capture.   

    The process was then validated by a physical inspection, confirming that the digital approach using raw data delivered the same level of assurance, accuracy, and safety as traditional methods. 

    The results confirmed that data-driven methodologies can match and potentially exceed the technical assurance and data integrity of conventional onboard physical surveys. While existing regulations still require physical attendance for survey requirements, this project demonstrates how verified operational data could allow for more efficient, transparent, and scalable compliance processes, reducing the need for physical attendance and enabling smarter fleet management. 

    Following the project success, LR and Latsco plan to jointly extend the methodology test across additional vessels and systems to validate the framework repeatability with the aim to establish a pilot scheme for digital class assurance.  

    Elina Papageorgiou, Vice President Greece and Cyprus, Lloyd’s Register, said: “This proof of concept gives confidence that digitalisation is an enabler within the maritime industry without compromising safety or integrity. By validating the use of verified operational data for survey assurance, we’re taking an important step towards a smarter, more connected maritime industry.” 

    Konstantinos Chatzitolios, Lead Client Relationship Manager, Lloyd’s Register, added: “Working closely with Latsco on this project has shown how strong collaboration and shared innovation can accelerate the adoption of digital class solutions. The success of this trial demonstrates what can be achieved when operational excellence and digital capability come together to redefine the future of ship classification.” 

    Antonis Georgantzis, COO, Latsco, said: “This initiative proves that trusted operational data can be used to credit survey requirements without compromising safety or technical integrity, while giving our vessels greater flexibility within increasingly tight trading schedules. This new approach will gradually reshape how we work, starting today.” 

    Iasonas Zacharioudakis, Technology Manager, Latsco, added: “Using telemetry, we verified that survey items can be credited on data-proven judgements with enhanced transparency and trust compared to the traditional approach. Raw data becomes a real operational and safety advantage.” 

    LR’s Digital Transformation Research Programme continues to advance the industry’s understanding of how digital technologies can enhance assurance, safety and operational performance. Central to this programme is the Digital Maturity Index (DMI), a framework designed to help shipowners assess and progress their digital capabilities. Remote surveys, such as the one demonstrated in this project, represent a key application within the DMI, showcasing how verified operational data can be used to deliver robust, data-driven assurance while supporting more efficient and resilient vessel operations. 

     

    Continue Reading